Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
November 18th, 2018
7.1K views
Left atrial stenosis (LAS) is a novel surgical technique used for studying group 2 pulmonary hypertension (PH) and mechanisms underlying pulmonary venous arterialization. Here, we present a protocol to constrict the left atrium using a titanium clip to cause pulmonary venous arterialization and moderate PH in a rat.
Overview
This article presents a protocol for performing left atrial stenosis (LAS) surgery in rats, a model for studying group 2 pulmonary hypertension (PH). The technique aims to induce pulmonary venous arterialization and moderate PH, contributing to the understanding of this prevalent condition.
Key Study Components
Area of Science
- Neuroscience
- Cardiovascular physiology
- Animal models of disease
Background
- Group 2 pulmonary hypertension is the most common form of PH.
- There are currently no approved therapies for this condition.
- Left atrial stenosis serves as a novel surgical model for studying PH mechanisms.
- This model helps in understanding pulmonary venous arterialization.
Purpose of Study
- To demonstrate the LAS surgical technique in rats.
- To investigate the mechanisms underlying group 2 pulmonary hypertension.
- To provide a protocol for researchers studying PH.
Methods Used
- Use of a titanium clip to constrict the left atrium.
- Induction of moderate pulmonary hypertension in rats.
- Step-by-step demonstration of the surgical procedure.
- Observation of physiological changes post-surgery.
Main Results
- Successful induction of pulmonary venous arterialization.
- Moderate pulmonary hypertension observed in the rat model.
- Protocol provides a reproducible method for future studies.
- Insights into the pathophysiology of group 2 pulmonary hypertension.
Conclusions
- Left atrial stenosis is a viable model for studying group 2 PH.
- The surgical technique can aid in understanding PH mechanisms.
- Further research is needed to explore potential therapies.
Frequently Asked Questions
What is left atrial stenosis?
Left atrial stenosis is a surgical technique used to study pulmonary hypertension by constricting the left atrium.
Why is this model important?
It helps researchers understand the mechanisms of group 2 pulmonary hypertension, which currently lacks approved therapies.
What are the main findings of this study?
The study successfully induced pulmonary venous arterialization and moderate PH in rats, providing a reproducible protocol for future research.
How is the surgery performed?
The surgery involves using a titanium clip to constrict the left atrium, which is demonstrated step-by-step in the article.
What are the implications of this research?
The findings may lead to better understanding and potential therapies for group 2 pulmonary hypertension.
Executive Industry Relevance
The left atrial stenosis (LAS) rat model enables mechanistic investigation of pulmonary venous arterialization and group 2 pulmonary hypertension (PH), a major unmet need in cardiovascular drug discovery. This model provides a reproducible platform for target validation and preclinical evaluation of therapeutic strategies addressing mitral stenosis-induced PH. Its translational alignment with human disease supports risk-adjusted portfolio decisions in early-stage cardiovascular R&D.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of disease mechanisms underlying group 2 PH and pulmonary venous remodeling.
- Supports functional target validation by recapitulating human mitral stenosis pathophysiology in vivo.
- Facilitates mechanistic de-risking for candidate targets implicated in pulmonary vascular remodeling.
- Provides a platform for hypothesis-driven exploration of molecular drivers of venous arterialization.
Screening & Assay Development
- Establishes a validated in vivo system for quantitative assessment of hemodynamic and histological endpoints.
- Enables reproducible measurement of transmitral inflow velocity and right ventricular systolic pressure.
- Supports standardization of preclinical screening for anti-PH compounds targeting group 2 mechanisms.
- Allows for scalable evaluation of candidate interventions in a disease-relevant context.
Translational & Preclinical Research
- Aligns with human disease features, including pulmonary congestion and vascular remodeling, for translational biomarker development.
- Provides continuity from mechanistic discovery to preclinical efficacy testing in a relevant animal model.
- Enables risk-adjusted advancement of therapeutic candidates targeting group 2 PH.
- Supports identification of predictive biomarkers for clinical translation.
Pipeline & Workflow Integration
This LAS rat model integrates into the discovery-to-preclinical continuum for cardiovascular drug development, bridging mechanistic studies and translational validation.
- Discovery Biology: Facilitates hypothesis testing and pathway clarification for group 2 PH targets.
- Screening: Provides quantitative, reproducible hemodynamic and histological readouts for compound evaluation.
- Analytics: Enables statistical comparison of disease progression and intervention effects using echocardiography and histology.
- Translational Research: Aligns preclinical findings with human disease features for biomarker and efficacy assessment.
- Enterprise Reuse: Offers a reusable, standardized model for ongoing cardiovascular R&D programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in group 2 PH research.
- Operational Value: Delivers standardized, reproducible, and scalable in vivo assessments.
- Strategic Value: Improves go/no-go decisions and capital efficiency by enabling early de-risking of targets and interventions.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of cardiovascular assets.
Implementation Considerations
- Requires expertise in rodent cardiovascular surgery and echocardiographic assessment.
- Needs access to specialized surgical instruments and imaging infrastructure.
- Demands rigorous cross-team standardization of surgical and analytical protocols.
- Adaptation may be needed for different rat strains or comorbid models.
- Careful titration of stenosis severity is essential to avoid acute complications and ensure model fidelity.
Biopharma FAQs
Why does null hypothesis testing matter for transmitral inflow velocity assessment?
Null hypothesis testing ensures that observed increases in transmitral inflow velocity post-LAS surgery are statistically significant, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation in LAS surgery fit the discovery pipeline?
Isolating left atrial constriction as the independent variable allows teams to attribute downstream pulmonary changes specifically to mitral stenosis, clarifying mechanistic pathways and informing target selection.
What do quantitative dependent variable measurements like right ventricular systolic pressure enable?
Quantitative measurements of right ventricular systolic pressure provide objective endpoints for comparing disease progression and therapeutic efficacy, enabling data-driven advancement decisions in preclinical studies.
Why are replication requirements critical for cross-functional collaboration in this model?
Replication of LAS-induced hemodynamic and histological changes ensures reproducibility across teams, facilitating reliable data sharing and coordinated decision-making in multi-site R&D programs.
Which statistical analysis capabilities are required before implementing LAS model studies?
Teams must be equipped to perform statistical comparisons of echocardiographic and histological data, including threshold-based group assignment and variance analysis, to support rigorous preclinical evaluation.
Chapters in this video
0:00
Title
1:20
Pre-operative Preparation
2:02
Anaesthesia and Endotracheal Intubation
3:11
Preparation of the Surgical Site
3:38
Left Atrial Stenosis Surgery
6:11
Confirm the Success of Left Atrial Stenosis with Echocardiography
6:21
Representative Results
7:43
Conclusion
